Celyad Oncology Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	0.02	0.19	0.1	-	-
Revenue Growth (YoY)	-88.71%	82.35%	-	-	-
Cost of Revenue	0.01	0.01	0.07	-	-
Gross Profit	0.01	0.17	0.03	-	-
Selling, General & Admin	3.78	3.2	6.03	10.55	9.91
Research & Development	3.42	3.24	4.6	18.93	20.77
Other Operating Expenses	0.19	0.04	0.19	35.42	1.47
Total Operating Expenses	7.39	6.47	10.82	64.9	32.15
Operating Income	0.88	-5.86	-8.46	-40.86	-26.39
Interest Income	0.01	0.15	0.03	0.19	0.14
Interest Expense	-0.06	-0.12	-0.08	-0.2	-0.26
Other Non-Operating Income (Expense)	8.26	0.44	2.33	24.04	5.76
Total Non-Operating Income (Expense)	8.2	0.47	2.28	24.03	5.65
Pretax Income	0.83	-5.82	-8.51	-40.87	-26.5
Provision for Income Taxes	-	-	0.06	-0.07	-0.01
Net Income	0.83	-5.82	-8.45	-40.94	-26.51
Net Income to Common	0.83	-5.82	-8.45	-40.94	-26.51
Shares Outstanding (Basic)	43	41	26	23	16
Shares Outstanding (Diluted)	43	41	26	23	16
Shares Change (YoY)	3.26%	61.06%	13.84%	44.80%	11.92%
EPS (Basic)	0.02	-0.14	-0.33	-1.81	-1.70
EPS (Diluted)	0.02	-0.14	-0.33	-1.81	-1.70
Free Cash Flow	-6.9	-5.68	-16.1	-28.13	-26.97
Free Cash Flow Per Share	-0.16	-0.14	-0.63	-1.25	-1.73
Gross Margin	61.90%	93.01%	32.35%	-	-
Operating Margin	4195.24%	-3149.46%	-8291.18%	-	-
Profit Margin	3952.38%	-3131.18%	-8282.35%	-	-
FCF Margin	-32857.10%	-3053.76%	-15785.30%	-	-
EBITDA	1.05	-5.41	-7.66	-39.42	-24.87
EBITDA Margin	5014.29%	-2907.53%	-7512.75%	-	-
EBIT	0.88	-5.86	-8.46	-40.86	-26.39
EBIT Margin	4195.24%	-3149.46%	-8291.18%	-	-
Effective Tax Rate	0.00%	0.00%	-0.74%	0.16%	0.04%